Multicenter clinical and mechanistic studies related to the quantitative efficacy of Huayu Tongluo Moxibustion in the treatment of vascular dementia

Multicenter clinical and mechanistic studies related to the quantitative efficacy of Huayu Tongluo Moxibustion in the treatment of vascular dementia - Multicenter clinical and mechanistic studies related to the quantitative efficacy of Huayu Tongluo Moxibustion in the treatment of vascular dementia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079428

Enrollment

Unknown

Registered

2024-01-03

Start date

2024-01-08

Completion date

Unknown

Last updated

2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular dementia

Interventions

Group A:Huayu Tongluo moxibustion 38°C+20 min group

Group B:Huayu Tongluo moxibustion 38°C +40 min group

Group C:Huayu Tongluo moxibustion 45°C+20 min group

Group D:Huayu Tongluo moxibustion 45°C+40 min group

Group E:Huayu Tongluo moxibustion and Acupuncture Group

Group F:Western medicine group

Eligibility

Sex/Gender

All

Age

45 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meets diagnostic criteria for VD; (2) Age between 45-85 years; (3) Montreal Cognitive Assessment Scale (MoCA) score between 16 and 26(26 points not included); (4) Cognitive dysfunction with a temporal association with cerebrovascular disease within 3 months; (5) Consciousness, no language barrier, and ability to cooperate in completing relevant scales; (6) Understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who exclude intracranial lesions other than cerebrovascular disease; (2) Patients with severe dementia; (3) Cognitive dysfunction caused by other non-vascular factors such as systemic diseases and the administration of medications affecting cognitive function; (4) Those with comorbidities of severe other systemic diseases that, in the opinion of the investigator, make them unsuitable for participation in the study; (5) Elderly patients with depression, or those with severe mental illness, severe visual, hearing, or speech disorders who are unable to cooperate; (6) Those who are currently undergoing other treatments that may affect the assessment of efficacy; (7) Those with contraindications to MRI examination (pacemaker, claustrophobia, etc.); (8) Those who are unable to cooperate with the experiment (e.g. refusing to sign the informed consent form and unable to insist on the whole experiment).

Design outcomes

Primary

Measure	Time frame
Montreal Cognitive Assessment Scale;	—

Secondary

Measure	Time frame
Mini-mental State Examination;Neurological Function Defect Scale;TMT-A;	—

Countries

China

Contacts

Public ContactYangjun

First Affiliated Hospital of Anhui University of Chinese Medicine

yangjunacup@126.com+86 189 0551 5173

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026